ClinicalTrials.gg
CompletedNCT06099535Updated Oct 25, 2023

A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis

A Phase 2 interventional study of LNK01001 Dose A and LNK01001 Dose B in Rheumatoid Arthritis, sponsored by Lynk Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by Lynk Pharmaceuticals Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Nov 2021, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Enrollment
93rd of 217
156 · median 134
Started
2021
with 14 others
Phase 2
34 of 249
8 open now
Registered
175th of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 93rd largest by enrollment of the 217 interventional ones that give a count, is one of 15 that started in 2021, is one of 34 in phase 2, and was the 175th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

This study includes two periods. In Period 1, Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B or a matching placebo for 12 weeks. Participants who receive a placebo in Period 1 will be re-randomized at Week 13 in a 1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B for 12 weeks (period 2). Participants who receive LNK01001 ( Dose A and Dose B) in Period 1 will maintain the treatment dose in Period 2.

Read the detailed description

This study includes a 35-day screening period; a 12-week randomized, double-blind, parallel-group, placebo-controlled treatment period (Period 1); a 12-week double-blind period (Period 2); and a 28 to 35-day follow-up period (FU).

Participants who meet eligibility criteria will be randomized in a ratio of 1:1:1 to 3 treatment groups in period 1, the placebo group will be rerandomized in a 1:1 ratio to LNK01001 Dose A or LNK01001 Dose B at week 13.

  1. Group 1: LNK01001 Dose A BID (Day 1 to Week 12), LNK01001 Dose A BID (Week 13 and thereafter)
  2. Group 2:LNK01001 Dose B BID (Day 1 to Week 12), LNK01001 Dose B BID (Week 13 and thereafter)
  3. Group 3: Placebo (Day 1 to Week12) , LNK01001 Dose A BID (Week 13 and thereafter)
  4. Group 4: Placebo (Day 1 to Week12) , LNK01001 Dose B BID (Week 13 and thereafter)

Participants who complete the Week 12 visit (end of Period 1) will enter Period 2, and continue to receive LNK01001 Dose A or Dose B treatment. Starting at Week 12, rescue therapy is allowed.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants between ≥ 18 and ≤70 years of age.
  • Diagnosis of RA for ≥ 3 months at screening visit who also fulfill the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) classification criteria for RA.
  • ≥ 6 swollen joints (based on 66 joint counts) and ≥ 6 tender joints (based on 68 joint counts) at Screening and baseline visit.
  • High-sensitivity C-Reactive Protein (hsCRP) ≥ at Screening.
  • Participants have been receiving csDMARD therapy ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are allergy to any component of the study drug.
  • Subjects who are ACR functional class IV or long-term bedridden/long-term wheelchair.
  • Prior exposure to Janus Kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
  • Subjects who received intra-articular, intramuscular, intravenous, trigger point or tender point, intracapsular, or intra-tendon injections of within 8 weeks before randomization.
  • Current use of oral or inhaled glucocorticoids and the daily dose is >10 mg of prednisone (or equivalent dose) or on a not stable dose within 4 weeks before randomization.
  • Current use of Non-steroidal anti-inflammatory drugs and on a not stable dose within 4 weeks before randomization.
  • Subjects who received iguratimod treatment within 4 weeks before randomization.
  • Subjects who received interferon treatment within 4 weeks before randomization.
  • Current diagnosis of systemic inflammatory disease other than RA.
  • History of or current diagnosis of malignancy within 5 years before screening visit.
  • Uncontrolled diabetes, hypertension, kidney disease, liver disease, severe heart disease.
  • Subject with any major surgery within 4 weeks before randomization or planned major surgery during study; history of chronic pain that may affect study evaluation; previous recipient of an organ transplant.
  • Any laboratory or abnormal value, as determined by the Investigator, may interfere with the evaluation of the study results.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    LNK01001 Dose A

    Participants will receive LNK01001 Dose A orally BID for up to 24 weeks.

    Drug: LNK01001 Dose A

  • Experimental
    LNK01001 Dose B

    Participants will receive LNK01001 Dose B orally BID for up to 24 weeks.

    Drug: LNK01001 Dose B

  • Placebo comparator
    placebo/LNK01001 Dose A

    Participants will receive a placebo orally BID for 12 weeks in Period 1. Participants will be re-randomized at Week 13 in a 1:1 ratio to receive LNK01001 Dose A orally BID for up to 24 weeks.

    Drug: LNK01001 Dose A · Drug: placebo

  • Placebo comparator
    placebo/LNK01001 Dose B

    Participants will receive a placebo orally BID for 12 weeks in Period 1. Participants will be re-randomized at Week 13 in a 1:1 ratio to receive LNK01001 Dose B orally BID for up to 24 weeks.

    Drug: LNK01001 Dose B · Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at week 12

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. 20% improvement in 68-tender joint count; 2. 20% improvement in 66-swollen joint count; and 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: week 12

Secondary outcomes

  1. Percentage of Participants With an ACR50

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: 1.50% improvement in 68-tender joint count; 2.50% improvement in 66-swollen joint count; and 3.50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Week1,2,4,8,12

  2. Percentage of Participants With an ACR20

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. 20% improvement in 68-tender joint count; 2. 20% improvement in 66-swollen joint count; and 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

    Time frame: Week1,2,4,8

  3. Change From Baseline in Disease Activity Score 28 (DAS28)-CRP

    The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity

    Time frame: Week1,2,4,8,12

  4. Change From Baseline in Disease Activity Score 28 (DAS28)-ESR

    The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and ESR. Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity

    Time frame: Week1,2,4,8,12

  5. Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI).

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Week1,2,4,8,12

  6. Percentage of Participants With an ACR70

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. 70% improvement in 68-tender joint count; 2. 70% improvement in 66-swollen joint count; and 3.70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Week1,2,4,8,12

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Dec 2022, 13 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 13 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Oct 25, 2023
StartActual
Nov 18, 2021
Primary completionActual
Dec 29, 2022
CompletionActual
Apr 11, 2023
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06099535
Lead sponsor
Lynk Pharmaceuticals Co., Ltd
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Nov 18, 2021
Primary completion
Dec 29, 2022
Completion
Apr 11, 2023
Last update
Oct 25, 2023

Study contacts

Xiaofeng Zeng
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zemprocitinib

Start the discussion